Gilead Sciences

$65.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.02%) Today
+$0.12 (+0.18%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
81.55B
Price-Earnings Ratio
Dividend Yield
4.03
Average Volume
10.47M
High Today
$65.17
Low Today
$64.05
Open Price
$64.95
Volume
14.26M
52 Week High
$85.97
52 Week Low
$60.89

Collections

GILD News

MarketWatchSep 15

The M&A surge: Is it rational exuberance or a frenzy before the market falls?

The M&A surge: Is it rational exuberance or a frenzy before the market falls? More The rise in equity markets and low funding costs encouraged chief executives
BloombergSep 14

Dealmakers See $69 Billion of M&A in Year’s Busiest Weekend

(Bloomberg) -- A blockbuster Sunday of takeovers has bled into Monday for the fastest start to a week for global dealmaking this year. Companies led by Japanes
BenzingaSep 14

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-sta

GILD Earnings

$0.00
$0.61
$1.21
$1.82
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Oct 22, After Hours

More GILD News

ReutersSep 14

Gilead's shares rise after $21 billion deal for Immunomedics

(Reuters) - Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premi
BloombergSep 14

Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal

(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer
Yahoo FinanceSep 14

Gilead Sciences to acquire Immunomedics in $21B deal

Gilead Sciences is set to acquire Immunomedics in a $21 billion dollar deal, which is expected to close in the fourth quarter of 2020. Dr. Behzad Aghazadeh, Imm
CNBCSep 14

Gilead CEO: We're studying new ways to treat coronavirus with remdesivir outside of the hospital

Gilead Sciences CEO Daniel O'Day told CNBC on Monday the company is continuing to study new ways to use its coronavirus treatment remdesivir on patients, includ
ReutersSep 14

Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics

(Reuters) - Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acces
BenzingaSep 14

A Look Into Gilead Sciences's Debt

Shares of Gilead Sciences (NASDAQ: GILD) fell by 12.82% in the past three months. Before having a look at the importance of debt, let us look at how much debt G
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.